- Investing Ideas
- Taiwanese Pharmaceuticals & Biotech Undervalued based on future growth
Taiwanese Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
1 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
Lotus Pharmaceutical
Market Cap: NT$50.6b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
New
1795
NT$198.00
7D
-0.3%
1Y
-12.6%
Bora Pharmaceuticals
Market Cap: NT$48.7b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$385.00
7D
6.1%
1Y
-41.8%